Cytotoxic T Lymphocyte Lines Specific for Human Immunodeficiency Virus Type 1 Gag and Reverse Transcriptase Derived from a Vertically Infected Child
Overview
Affiliations
Cytotoxic T lymphocytes (CTL) specific for human immunodeficiency virus type 1 (HIV-1) are thought to play an important role in controlling HIV-1 infection. HIV-1-specific CTL are readily demonstrated in unstimulated peripheral blood mononuclear cells (PBMC) of HIV-infected adults but less frequently in PBMC from vertically infected children. HIV-1-specific CTL lines were derived from a long-term survivor of vertical HIV-1 infection using PBMC stimulated with a CD3-specific monoclonal antibody and interleukin-2; these lines had Gag- or reverse transcriptase (RT)-specific cytotoxicity. Cytotoxicity was restricted by major histocompatibility complex class I antigen and blocked by antibody to the T cell receptor complex. Fluorescence-activated cell sorting analysis demonstrated their phenotype to be CD3+CD4-CD8+. Unstimulated PBMC from this patient had no detectable HIV-1-specific cytotoxicity when tested against autologous HIV-1 envelope-, Gag-, or RT-expressing target cells. Thus, this child with vertically acquired HIV-1 infection likely has HIV-1-specific CTL precursors despite the absence of circulating, activated HIV-1-specific CTL.
The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8+ T cells.
Gutjahr A, Papagno L, Nicoli F, Kanuma T, Kuse N, Cabral-Piccin M JCI Insight. 2019; 4(7).
PMID: 30944257 PMC: 6483644. DOI: 10.1172/jci.insight.125107.
Liu S, Schacker T, Musey L, Shriner D, McElrath M, Corey L J Virol. 1997; 71(6):4284-95.
PMID: 9151816 PMC: 191644. DOI: 10.1128/JVI.71.6.4284-4295.1997.
HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women.
Musey L, Hu Y, Eckert L, Christensen M, Karchmer T, McElrath M J Exp Med. 1997; 185(2):293-303.
PMID: 9016878 PMC: 2196121. DOI: 10.1084/jem.185.2.293.
Ganeshan S, Dickover R, Korber B, Bryson Y, Wolinsky S J Virol. 1997; 71(1):663-77.
PMID: 8985398 PMC: 191099. DOI: 10.1128/JVI.71.1.663-677.1997.
Purner M, Berens R, Nash P, van Linden A, Ross E, Kruse C Infect Immun. 1996; 64(10):4330-8.
PMID: 8926107 PMC: 174375. DOI: 10.1128/iai.64.10.4330-4338.1996.